Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE

   Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer
                          Reviewed Journal PLOS ONE

Study assessed effectiveness of ORMD-0801 in stabilizing blood sugar levels in
unstable Type 1 diabetes patients

PR Newswire

JERUSALEM, May 1, 2013

JERUSALEM, May 1, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral delivery systems of drugs currently administered by
injection, announced today that its article titled, "Glucose-reducing effect
of the ORMD-0801 oral insulin preparation in patients with uncontrolled Type 1
diabetes: a pilot study," has been published in PLOS ONE, an international,
peer-reviewed, open-access journal which covers primary scientific and medical
research.

The article details the results of a clinical study, in which ORMD-0801 was
administered to patients with unstable Type 1 diabetes, in conjunction with
their regular anti-diabetes treatment regimens. These patients typically
suffer from unpredictable and frequent swings in their blood sugar levels,
which often demand hospitalization and severely disrupt their quality of life.
The addition of ORMD-0801 was well tolerated and significantly stabilized
blood sugar levels in this patient group. A significant drop in the frequency
of above-normal blood sugar readings was observed, as well as a decrease in
overall blood sugar levels throughout the day. 

"These published results lay the groundwork for further study of the potential
of ORMD-0810 as a treatment that can considerably aid a patient population
resistant to standard anti-diabetes treatment protocols," stated Oramed CEO
Nadav Kidron.

The article can be viewed on PLOS ONE's site, the content of which is not part
of this press release, at:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059524

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
approaching Phase 2 clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a
trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com.

The company's fact sheet,the content of which is not part of this press
release, can be viewedhere.

Forward-looking statements: This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and federal securities laws. For
example, we are using forward-looking statements when we discuss the potential
of ORMD-0810 as a treatment that can considerably aid a patient population
resistant to standard anti-diabetes treatment protocols or our oral insulin
and oral exenatide candidates approaching Phase 2 clinical trials and 2a
clinical trials, respectively. These forward-looking statements are based on
the current expectations of the management of Oramed only, and are subject to
a number of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs; difficulties
or delays in obtaining regulatory approval or patent protection for our
product candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In addition, the
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in launching our
clinical trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our methods by
the scientific community; inability to retain or attract key employees whose
knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of
final product than anticipated; loss of market share and pressure on pricing
resulting from competition; laboratory results that do not translate to
equally good results in real settings; our patents may not be sufficient; and
final that products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those contemplated
in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.